Iulia Alekseevna Levina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Iulia Alekseevna Levina has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Sergey Nikolaevich Avdeev
Sechenov First Moscow State Medical University, Moscow, Russia
24 shared publications - Natalia Vladimirovna Trushenko
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation
21 shared publications - Baina Baatrovna Lavginova
Sechenov First Moscow State Medical University (Sechenov University)
19 shared publications - Olga Alexandrovna Suvorova
Pulmonology Department, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia
16 shared publications - Zamira Magomedovna Merzhoeva
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
11 shared publications - Galina Vasilyevna Nekludova
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation
7 shared publications
Latest Publications
- Open Access
- 18 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3383
Shared Enrichment of the MUC5B Variant rs35705950 in Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis: Evidence from a Russian Cohort
Background/Objectives: The MUC5B rs35705950 polymorphism is the strongest common genetic risk factor for idiopathic pulmonary fibrosis (IPF), whereas its role in fibrotic hypersensitivity pneumonitis (fHP) remains incompletely characterized, particularly in Eastern European cohorts. This study aimed to evaluate the distribution of MUC5B rs35705950 genotypes and alleles in Russian patients with IPF and fHP and to assess their association with disease susceptibility using a large external Russian reference dataset. Methods: The study included 114 patients with interstitial lung disease: 50 with IPF and 64 with fHP. Genotyping was performed using a custom PCR-restriction fragment length polymorphism assay. Genotype and allele frequencies were compared with an external reference dataset from the National Genetic Initiative of Russia (n = 89,261). Association analyses were performed under dominant T-carrier and allelic models. Results: The rs35705950 T allele was significantly enriched in both IPF and fHP compared with the external reference dataset. T-carrier genotypes were detected in 52.0% of patients with IPF and 42.2% of patients with fHP, compared with 18.9% in the reference dataset. T-allele frequencies were 28.0%, 26.6%, and 10.0%, respectively. In the dominant model, T-carrier status was associated with increased odds of IPF (OR = 4.65; 95% CI, 2.56–8.46; p < 0.001) and fHP (OR = 3.13; 95% CI, 1.83–5.29; p < 0.001). The direct comparison between IPF and fHP was inconclusive because of limited statistical power. Conclusions: In this Russian clinical cohort, the rs35705950 T allele was more frequent in patients with IPF and fHP than in the external Russian reference dataset. These findings provide regional replication of previously reported associations. The study did not assess causal mechanisms or diagnostic performance.
- 18 October 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (20) , 3383
Open AccessShared Enrichment of the MUC5B Variant rs35705950 in Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis: Evidence from a Russian Cohort
Background/Objectives: The MUC5B rs35705950 polymorphism is the strongest common genetic risk factor for idiopathic pulmonary fibrosis (IPF), whereas its role in fibrotic hypersensitivity pneumonitis (fHP) remains incompletely characterized, particularly in Eastern European cohorts. This study aimed to evaluate the distribution of MUC5B rs35705950 genotypes and alleles in Russian patients with IPF and fHP and to assess their association with disease susceptibility using a large external Russian reference dataset. Methods: The study included 114 patients with interstitial lung disease: 50 with IPF and 64 with fHP. Genotyping was performed using a custom PCR-restriction fragment length polymorphism assay. Genotype and allele frequencies were compared with an external reference dataset from the National Genetic Initiative of Russia (n = 89,261). Association analyses were performed under dominant T-carrier and allelic models. Results: The rs35705950 T allele was significantly enriched in both IPF and fHP compared with the external reference dataset. T-carrier genotypes were detected in 52.0% of patients with IPF and 42.2% of patients with fHP, compared with 18.9% in the reference dataset. T-allele frequencies were 28.0%, 26.6%, and 10.0%, respectively. In the dominant model, T-carrier status was associated with increased odds of IPF (OR = 4.65; 95% CI, 2.56–8.46; p < 0.001) and fHP (OR = 3.13; 95% CI, 1.83–5.29; p < 0.001). The direct comparison between IPF and fHP was inconclusive because of limited statistical power. Conclusions: In this Russian clinical cohort, the rs35705950 T allele was more frequent in patients with IPF and fHP than in the external Russian reference dataset. These findings provide regional replication of previously reported associations. The study did not assess causal mechanisms or diagnostic performance.
- 14 October 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (3)
Remote monitoring of patients with chronic obstructive pulmonary disease: results of a multicentre pilot study
Objective. To evaluate the results of a multicentre randomized pilot study of remote monitoring (RM) in patients with chronic obstructive pulmonary disease (COPD). Material and methods. A multicentre, randomized, open-label study. Patients with a verified diagnosis of COPD were randomized 1:1 to either the RM group or the standard follow-up care group (control): a total of 67 patients were enrolled (RM — 33, control — 34). The participation duration was 14 weeks. This paper presents the results of the analysis of patients enrolled at the time of publication preparation (Sechenov University centre). The analysis was performed in the mITT population (N=55: RM 29 patients, control 26). The primary endpoint included: relative change in FEV1, absolute change in the frequency of short-acting bronchodilator (SABD) use, and estimated annual exacerbation rate of COPD at week 12. Results. The relative change in FEV1 at week 12 was +2.65% in the RM group and −6.55% in the control group; the absolute FEV1 value was 70.15% vs 59.99% of predicted (p=0.164). The RM group showed a reduction in the estimated annual COPD exacerbation rate (1.38 vs 2.12; p=0.016); however, this result requires cautious interpretation given the correction for multiple comparisons; the categorical distribution of exacerbations differed significantly (p=0.008). The frequency of SABD use at week 12 was 1.19 vs 1.69 doses/day (p=0.098). The CAT score consistently decreased in the RM group: −2.04 (p=0.021), −2.91 (p=0.020), and −3.33 (p=0.012) at weeks 2, 6, and 12, respectively. The proportion of patients with severe dyspnoea on the Borg scale (≥5 points) was significantly lower in the RM group at week 12 (p=0.027). Mean adherence to monitoring exceeded 80% across all parameters. No unplanned healthcare visits were recorded in the RM group vs 3 cases (11.54%) in the control group (p=0.099). Conclusion. The RM group demonstrated a reduction in the estimated annual COPD exacerbation rate, as well as sustained positive trends in functional and symptomatic outcomes. High patient adherence confirms the feasibility of the RM programme in real-world practice. The findings highlight the need to continue the study in order to obtain more robust data.
- 14 October 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (3)
Remote monitoring of patients with chronic obstructive pulmonary disease: results of a multicentre pilot study
Objective. To evaluate the results of a multicentre randomized pilot study of remote monitoring (RM) in patients with chronic obstructive pulmonary disease (COPD). Material and methods. A multicentre, randomized, open-label study. Patients with a verified diagnosis of COPD were randomized 1:1 to either the RM group or the standard follow-up care group (control): a total of 67 patients were enrolled (RM — 33, control — 34). The participation duration was 14 weeks. This paper presents the results of the analysis of patients enrolled at the time of publication preparation (Sechenov University centre). The analysis was performed in the mITT population (N=55: RM 29 patients, control 26). The primary endpoint included: relative change in FEV1, absolute change in the frequency of short-acting bronchodilator (SABD) use, and estimated annual exacerbation rate of COPD at week 12. Results. The relative change in FEV1 at week 12 was +2.65% in the RM group and −6.55% in the control group; the absolute FEV1 value was 70.15% vs 59.99% of predicted (p=0.164). The RM group showed a reduction in the estimated annual COPD exacerbation rate (1.38 vs 2.12; p=0.016); however, this result requires cautious interpretation given the correction for multiple comparisons; the categorical distribution of exacerbations differed significantly (p=0.008). The frequency of SABD use at week 12 was 1.19 vs 1.69 doses/day (p=0.098). The CAT score consistently decreased in the RM group: −2.04 (p=0.021), −2.91 (p=0.020), and −3.33 (p=0.012) at weeks 2, 6, and 12, respectively. The proportion of patients with severe dyspnoea on the Borg scale (≥5 points) was significantly lower in the RM group at week 12 (p=0.027). Mean adherence to monitoring exceeded 80% across all parameters. No unplanned healthcare visits were recorded in the RM group vs 3 cases (11.54%) in the control group (p=0.099). Conclusion. The RM group demonstrated a reduction in the estimated annual COPD exacerbation rate, as well as sustained positive trends in functional and symptomatic outcomes. High patient adherence confirms the feasibility of the RM programme in real-world practice. The findings highlight the need to continue the study in order to obtain more robust data.
- Open Access
- 8 October 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (5) , 871-882
Triple combination ivacaftor + tezacaftor + elexacaftor and ivacaftor for cystic fibrosis: clinical efficacy and safety of the original drug and its generic analogue Trilexa®
Triple CFTR modulator therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor (ITE) has substantially changed the clinical course and prognosis of cystic fibrosis. The expanding use of the bioequivalent generic Trilexa® highlights the need to summarize evidence on its clinical efficacy and safety, including outcomes after switching from the originator Trikafta®. The aim of this study was to summarize and systematize national and international data on the efficacy and safety of triple CFTR modulator therapy with ITE, including the experience of using the original drug and the generic drug, in children and adults with cystic fibrosis. Results. The triple ITE combination is the most widely studied and the most effective of the available methods of pathogenetic therapy for cystic fibrosis. In randomized clinical trials and observational programs, the originator provides an increase in FEV 1, a marked reduction in sweat chloride concentration, improvement in nutritional status, and a significant decrease in the rate of pulmonary exacerbations. Bioequivalence of the generic drug has been confirmed. Russian multicenter and regional studies convincingly show that switching from the originator to bioequivalent generic is accompanied by maintenance of FEV1, FVC, nutritional status, and surrogate markers of CFTR function, while preserving a favorable safety profile. The accumulated clinical experience includes the first documented case of a successfully completed pregnancy and delivery under treatment with a generic ITE regimen. Data from studies evaluating the efficacy and safety of deutivacaftor + tezacaftor + vanzacaftor as a new option for triple CFTR modulator therapy were additionally reviewed. Conclusion. The body of evidence from international randomized clinical trials, registry studies, and Russian regional experience indicates clinical comparability between the originator and bioequivalent generic when switching from one to another. The use of a bioequivalent generic is a justified strategy to improve the availability of pathogenetic treatment with the goal to expand access to targeted therapy.
- 8 October 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (5) , 871-882
Open AccessTriple combination ivacaftor + tezacaftor + elexacaftor and ivacaftor for cystic fibrosis: clinical efficacy and safety of the original drug and its generic analogue Trilexa®
Triple CFTR modulator therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor (ITE) has substantially changed the clinical course and prognosis of cystic fibrosis. The expanding use of the bioequivalent generic Trilexa® highlights the need to summarize evidence on its clinical efficacy and safety, including outcomes after switching from the originator Trikafta®. The aim of this study was to summarize and systematize national and international data on the efficacy and safety of triple CFTR modulator therapy with ITE, including the experience of using the original drug and the generic drug, in children and adults with cystic fibrosis. Results. The triple ITE combination is the most widely studied and the most effective of the available methods of pathogenetic therapy for cystic fibrosis. In randomized clinical trials and observational programs, the originator provides an increase in FEV 1, a marked reduction in sweat chloride concentration, improvement in nutritional status, and a significant decrease in the rate of pulmonary exacerbations. Bioequivalence of the generic drug has been confirmed. Russian multicenter and regional studies convincingly show that switching from the originator to bioequivalent generic is accompanied by maintenance of FEV1, FVC, nutritional status, and surrogate markers of CFTR function, while preserving a favorable safety profile. The accumulated clinical experience includes the first documented case of a successfully completed pregnancy and delivery under treatment with a generic ITE regimen. Data from studies evaluating the efficacy and safety of deutivacaftor + tezacaftor + vanzacaftor as a new option for triple CFTR modulator therapy were additionally reviewed. Conclusion. The body of evidence from international randomized clinical trials, registry studies, and Russian regional experience indicates clinical comparability between the originator and bioequivalent generic when switching from one to another. The use of a bioequivalent generic is a justified strategy to improve the availability of pathogenetic treatment with the goal to expand access to targeted therapy.
- Open Access
- 5 October 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (9) , 705-712
Clinical and prognostic significance of intrathoracic lymphadenopathy in fibrosing interstitial lung diseases
Background. Mediastinal lymph node (MLN) enlargement is a common radiological finding in fibrosing interstitial lung diseases (fILDs). However, its clinical and prognostic significance across different disease entities remains poorly characterized. Aim. To assess the prevalence of intrathoracic lymphadenopathy in idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (fHP), and systemic sclerosis-associated fibrosing interstitial lung disease (fILD-SSc), and to determine its associations with disease characteristics, progression, and prognosis. Materials and methods. This retrospective two-center cohort study included 533 patients: 151 with IPF, 279 with fHP, and 103 with fILD-SSc. MLN enlargement was defined as a lymph node short-axis diameter ≥ 10 mm. The number of enlarged MLNs was also assessed semiquantitatively. Logistic regression, Kaplan–Meier analysis, and Cox regression were used to evaluate prognostic significance. Results. Intrathoracic lymphadenopathy was detected in 39.4% of patients with IPF, 57.0% with fHP, and 36.2% with fILD-SSc (p = 0.001). In the overall cohort, enlarged MLNs were associated with a usual interstitial pneumonia pattern (odds ratio – OR 1.69, 95% confidence interval – CI 1.18–2.44; p = 0.004) and mortality (OR 3.39, 95% CI 2.11–5.45; p 0.0001). The association with mortality was confirmed by Kaplan–Meier analysis (p = 0.028) and Cox regression (hazard ratio 1.50, 95% CI 1.03–2.17; p = 0.033). In IPF, MLN enlargement was associated with mortality (OR 5.83; p = 0.001), whereas in fHP it was associated with both disease progression (OR 2.53; p = 0.001) and mortality (OR 3.59; p 0.0001). In fILD-SSc, intrathoracic lymphadenopathy was associated with a greater extent of lung involvement as assessed by the Goh score (β = 0.219; p = 0.026), but not with disease progression or prognosis. Conclusion. MLN enlargement is a radiological feature associated with an unfavorable course of fILD, with the strongest prognostic significance observed in IPF and fHP. Semiquantitative assessment of the number of enlarged MLNs did not demonstrate prognostic significance.
- 5 October 2026
- Published by Consilium Medicum in Consilium Medicum
- Vol. 28 (9) , 705-712
Open AccessClinical and prognostic significance of intrathoracic lymphadenopathy in fibrosing interstitial lung diseases
Background. Mediastinal lymph node (MLN) enlargement is a common radiological finding in fibrosing interstitial lung diseases (fILDs). However, its clinical and prognostic significance across different disease entities remains poorly characterized. Aim. To assess the prevalence of intrathoracic lymphadenopathy in idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (fHP), and systemic sclerosis-associated fibrosing interstitial lung disease (fILD-SSc), and to determine its associations with disease characteristics, progression, and prognosis. Materials and methods. This retrospective two-center cohort study included 533 patients: 151 with IPF, 279 with fHP, and 103 with fILD-SSc. MLN enlargement was defined as a lymph node short-axis diameter ≥ 10 mm. The number of enlarged MLNs was also assessed semiquantitatively. Logistic regression, Kaplan–Meier analysis, and Cox regression were used to evaluate prognostic significance. Results. Intrathoracic lymphadenopathy was detected in 39.4% of patients with IPF, 57.0% with fHP, and 36.2% with fILD-SSc (p = 0.001). In the overall cohort, enlarged MLNs were associated with a usual interstitial pneumonia pattern (odds ratio – OR 1.69, 95% confidence interval – CI 1.18–2.44; p = 0.004) and mortality (OR 3.39, 95% CI 2.11–5.45; p 0.0001). The association with mortality was confirmed by Kaplan–Meier analysis (p = 0.028) and Cox regression (hazard ratio 1.50, 95% CI 1.03–2.17; p = 0.033). In IPF, MLN enlargement was associated with mortality (OR 5.83; p = 0.001), whereas in fHP it was associated with both disease progression (OR 2.53; p = 0.001) and mortality (OR 3.59; p 0.0001). In fILD-SSc, intrathoracic lymphadenopathy was associated with a greater extent of lung involvement as assessed by the Goh score (β = 0.219; p = 0.026), but not with disease progression or prognosis. Conclusion. MLN enlargement is a radiological feature associated with an unfavorable course of fILD, with the strongest prognostic significance observed in IPF and fHP. Semiquantitative assessment of the number of enlarged MLNs did not demonstrate prognostic significance.
- Open Access
- 27 August 2026
- Published by Open Systems Publications in Лечащий врач
- No. 7-8(29),p. 102-109
Triple CFTR modulator therapy in severe cystic fibrosis-associated liver disease: a case report of an adverse outcome and the role of adherence to follow-up
Background. Cystic fibrosis (CF) is a multisystem disease in which liver involvement occurs in 20-40% of patients. The introduction of CFTR modulator therapy has substantially improved the prognosis of patients with CF; however, patients with established cirrhosis have typically been excluded from clinical trials, which limits the evidence base and underscores the need to collect and publish data on the use of these agents in this patient group. Materials and methods. We report a case with an unfavorable outcome in a 19-year-old patient with CF-associated Child-Pugh class B cirrhosis complicated by portal hypertension and a previous episode of esophageal variceal bleeding. Triple CFTR modulator therapy with elexacaftor + tezacaftor + ivacaftor/ivacaftor was initiated as a life-saving measure at a reduced dose in order to stabilize the patient until a decision on liver transplantation could be made. However, following subjective improvement in respiratory status, the patient was lost to specialist follow-up for approximately two years, during which liver function was not monitored and the transplant workup was not advanced; this culminated in decompensation of cirrhosis (Child-Pugh class C), multiorgan failure, and death. Conclusion. This case demonstrates that in severe CF-associated liver disease the safety of highly effective targeted therapy depends not only on the choice of drug and the dosing regimen, but also on the continuity of specialist follow-up, regular assessment of liver function, timely adjustment of treatment and transplant strategy, and the patient's adherence to follow-up.
- 27 August 2026
- Published by Open Systems Publications in Лечащий врач
- No. 7-8(29),p. 102-109
Open AccessTriple CFTR modulator therapy in severe cystic fibrosis-associated liver disease: a case report of an adverse outcome and the role of adherence to follow-up
Background. Cystic fibrosis (CF) is a multisystem disease in which liver involvement occurs in 20-40% of patients. The introduction of CFTR modulator therapy has substantially improved the prognosis of patients with CF; however, patients with established cirrhosis have typically been excluded from clinical trials, which limits the evidence base and underscores the need to collect and publish data on the use of these agents in this patient group. Materials and methods. We report a case with an unfavorable outcome in a 19-year-old patient with CF-associated Child-Pugh class B cirrhosis complicated by portal hypertension and a previous episode of esophageal variceal bleeding. Triple CFTR modulator therapy with elexacaftor + tezacaftor + ivacaftor/ivacaftor was initiated as a life-saving measure at a reduced dose in order to stabilize the patient until a decision on liver transplantation could be made. However, following subjective improvement in respiratory status, the patient was lost to specialist follow-up for approximately two years, during which liver function was not monitored and the transplant workup was not advanced; this culminated in decompensation of cirrhosis (Child-Pugh class C), multiorgan failure, and death. Conclusion. This case demonstrates that in severe CF-associated liver disease the safety of highly effective targeted therapy depends not only on the choice of drug and the dosing regimen, but also on the continuity of specialist follow-up, regular assessment of liver function, timely adjustment of treatment and transplant strategy, and the patient's adherence to follow-up.
- Open Access
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 142-149
Comorbidities and predictors of unfavorable prognosis in hypersensitivity pneumonitis
Introduction . Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease characterized by inflammation and/or pulmonary fibrosis. Fibrotic HP (fHP) is associated with an unfavorable prognosis, however, the impact of comorbidities on disease progression and outcomes remains insufficiently studied. Aim . To assess the prevalence and clinical significance of comorbidities and to identify predictors of disease progression and mortality in patients with fibrotic and non-fibrotic HP (non-fHP). Materials and methods . This prospective observational study included 392 patients with multidisciplinary-confirmed HP. The follow-up period was 12 months. Clinical, functional, and radiological characteristics, Charlson comorbidity index, 6-minute walk test (6-MWT), echocardiographic parameters were evaluated. Disease progression was assessed according to the ATS/ ERS/JRS/ALAT 2022 criteria. Logistic regression and ROC analyses were used to identify predictors of progression and mortality. Results. A total of 339 patients were included in the analysis: 89.9% with fHP and 11.1% with non-fHP. Patients with fHP were older and demonstrated higher GAP scores, more severe dyspnea and cough, poorer 6-MWT performance, and higher mortality compared with non-fHP. Patients with fHP also had higher Charlson comorbidity index values (4 (2-5) vs 2 (1-4), p = 0.003) and a higher prevalence of cardiovascular diseases. A usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography was an independent predictor of progression (OR 3.16, 95% CI 1.06–9.46). Predictors of mortality included unidentified causative antigen exposure, oxygen desaturation at the end of the 6-MWT, Charlson comorbidity index ≥ 4, and left ventricular ejection fraction ≤ 55%. Diabetes mellitus was also associated with an increased risk of progression and mortality (OR 2.58, 95% CI 1.19–5.56, p = 0.016). Conclusion . Patients with fHP are characterized by a high burden of comorbidities, particularly cardiovascular diseases and diabetes mellitus. UIP pattern, unidentified causative antigen exposure, significant oxygen desaturation during the 6-MWT, and a high Charlson comorbidity index have a substantial impact on disease prognosis.
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 142-149
Open AccessComorbidities and predictors of unfavorable prognosis in hypersensitivity pneumonitis
Introduction . Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease characterized by inflammation and/or pulmonary fibrosis. Fibrotic HP (fHP) is associated with an unfavorable prognosis, however, the impact of comorbidities on disease progression and outcomes remains insufficiently studied. Aim . To assess the prevalence and clinical significance of comorbidities and to identify predictors of disease progression and mortality in patients with fibrotic and non-fibrotic HP (non-fHP). Materials and methods . This prospective observational study included 392 patients with multidisciplinary-confirmed HP. The follow-up period was 12 months. Clinical, functional, and radiological characteristics, Charlson comorbidity index, 6-minute walk test (6-MWT), echocardiographic parameters were evaluated. Disease progression was assessed according to the ATS/ ERS/JRS/ALAT 2022 criteria. Logistic regression and ROC analyses were used to identify predictors of progression and mortality. Results. A total of 339 patients were included in the analysis: 89.9% with fHP and 11.1% with non-fHP. Patients with fHP were older and demonstrated higher GAP scores, more severe dyspnea and cough, poorer 6-MWT performance, and higher mortality compared with non-fHP. Patients with fHP also had higher Charlson comorbidity index values (4 (2-5) vs 2 (1-4), p = 0.003) and a higher prevalence of cardiovascular diseases. A usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography was an independent predictor of progression (OR 3.16, 95% CI 1.06–9.46). Predictors of mortality included unidentified causative antigen exposure, oxygen desaturation at the end of the 6-MWT, Charlson comorbidity index ≥ 4, and left ventricular ejection fraction ≤ 55%. Diabetes mellitus was also associated with an increased risk of progression and mortality (OR 2.58, 95% CI 1.19–5.56, p = 0.016). Conclusion . Patients with fHP are characterized by a high burden of comorbidities, particularly cardiovascular diseases and diabetes mellitus. UIP pattern, unidentified causative antigen exposure, significant oxygen desaturation during the 6-MWT, and a high Charlson comorbidity index have a substantial impact on disease prognosis.
- Open Access
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 123-130
Clinical potential of inhaled tauractant in patients with progressive pulmonary fibroses
Introduction . Progressive pulmonary fibrosis (PPF) is characterized by relentless decline in lung function, poor prognosis, and limited therapeutic options. Exogenous surfactant is considered a potential pathogenetic agent. Aim. To evaluate the efficacy and safety of inhaled Surfactant-BL (INN: tauractant, a natural surfactant from bovine lungs) as an add-on to standard therapy in patients with PPF. Materials and methods . A single-center prospective randomized open-label controlled trial was conducted. 71 patients with PPF were assigned to three groups: surfactant 75 mg (n = 21), 150 mg (n = 19) or control (n = 31). Inhalations were administered twice daily for 10 days. Results . In the pooled surfactant group, by day 10 respiratory rate decreased from 22 (19–22) to 20 (18–21) breaths/min (p = 0.03) and SpO 2 increased from 93 (85–94)% to 94 (92–96)% (p = 0.028); by day 30, forced vital capacity (FVC) increased from 65 (45–77)% to 73 (64–83)% of predicted (p = 0.05). No dose-dependent differences were observed. In the 150 mg group, transient cough worsening occurred by day 10 (p = 0.013) followed by improvement by day 30 (p = 0.021). In patients with PaO 2 /FiO 2 < 300 mmHg, PaO₂ increased by day 30 (p = 0.042), while those with PaO2/FiO2 > 300 mmHg showed increased SpO 2 by day 10 (p = 0.0006). A baseline FVC predicted response (SpO 2 increase ≥ 4%; OR 1.08, 95% CI 1.03–1.14; p = 0.003) with an optimal threshold of 70% predicted (AUC 0.787). In patients with FVC > 70% predicted, surfactant demonstrated advantages over control at day 30 for SpO 2 (95% vs. 93%, p = 0.052) and DLco (52.5% vs. 40.0%, p = 0.046). Conclusions . Inhaled surfactant represents a pathogenetically justified and effective add-on to standard therapy for PPF. The greatest benefit is achieved in patients with FVC > 70% predicted, hypoxemic respiratory failure, and refractory cough.
- 14 July 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 123-130
Open AccessClinical potential of inhaled tauractant in patients with progressive pulmonary fibroses
Introduction . Progressive pulmonary fibrosis (PPF) is characterized by relentless decline in lung function, poor prognosis, and limited therapeutic options. Exogenous surfactant is considered a potential pathogenetic agent. Aim. To evaluate the efficacy and safety of inhaled Surfactant-BL (INN: tauractant, a natural surfactant from bovine lungs) as an add-on to standard therapy in patients with PPF. Materials and methods . A single-center prospective randomized open-label controlled trial was conducted. 71 patients with PPF were assigned to three groups: surfactant 75 mg (n = 21), 150 mg (n = 19) or control (n = 31). Inhalations were administered twice daily for 10 days. Results . In the pooled surfactant group, by day 10 respiratory rate decreased from 22 (19–22) to 20 (18–21) breaths/min (p = 0.03) and SpO 2 increased from 93 (85–94)% to 94 (92–96)% (p = 0.028); by day 30, forced vital capacity (FVC) increased from 65 (45–77)% to 73 (64–83)% of predicted (p = 0.05). No dose-dependent differences were observed. In the 150 mg group, transient cough worsening occurred by day 10 (p = 0.013) followed by improvement by day 30 (p = 0.021). In patients with PaO 2 /FiO 2 < 300 mmHg, PaO₂ increased by day 30 (p = 0.042), while those with PaO2/FiO2 > 300 mmHg showed increased SpO 2 by day 10 (p = 0.0006). A baseline FVC predicted response (SpO 2 increase ≥ 4%; OR 1.08, 95% CI 1.03–1.14; p = 0.003) with an optimal threshold of 70% predicted (AUC 0.787). In patients with FVC > 70% predicted, surfactant demonstrated advantages over control at day 30 for SpO 2 (95% vs. 93%, p = 0.052) and DLco (52.5% vs. 40.0%, p = 0.046). Conclusions . Inhaled surfactant represents a pathogenetically justified and effective add-on to standard therapy for PPF. The greatest benefit is achieved in patients with FVC > 70% predicted, hypoxemic respiratory failure, and refractory cough.
- 2 July 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (2)
Case of targeted therapy in a patient with cystic fibrosis and decompensated liver cirrhosis
Cystic fibrosis (CF) is a multisystem disease in which liver involvement may progress to cirrhosis and portal hypertension. The introduction of CFTR modulator therapy has significantly improved the prognosis of patients with CF; however, the use of these agents in patients with decompensated liver cirrhosis remains limited due to the risk of drug-induced liver injury and the lack of clinical data. We present a clinical case of combination therapy with ivacaftor+tezacaftor+elexacaftor/ivacaftor in a 29-year-old patient with CF (F508del/F508del genotype), decompensated Child—Pugh C liver cirrhosis, and placement on the liver transplantation waiting list. During 6 months of therapy, stabilization of respiratory status, reduction in the severity of respiratory failure, and improvement in liver function parameters and nutritional status were observed. No clinically significant adverse events or signs of drug-induced liver injury were recorded. This clinical observation demonstrates the potential feasibility of CFTR modulator therapy in selected patients with severe CF-associated liver disease, provided that a multidisciplinary approach and careful clinical and laboratory monitoring are ensured.
- 2 July 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (2)
Case of targeted therapy in a patient with cystic fibrosis and decompensated liver cirrhosis
Cystic fibrosis (CF) is a multisystem disease in which liver involvement may progress to cirrhosis and portal hypertension. The introduction of CFTR modulator therapy has significantly improved the prognosis of patients with CF; however, the use of these agents in patients with decompensated liver cirrhosis remains limited due to the risk of drug-induced liver injury and the lack of clinical data. We present a clinical case of combination therapy with ivacaftor+tezacaftor+elexacaftor/ivacaftor in a 29-year-old patient with CF (F508del/F508del genotype), decompensated Child—Pugh C liver cirrhosis, and placement on the liver transplantation waiting list. During 6 months of therapy, stabilization of respiratory status, reduction in the severity of respiratory failure, and improvement in liver function parameters and nutritional status were observed. No clinically significant adverse events or signs of drug-induced liver injury were recorded. This clinical observation demonstrates the potential feasibility of CFTR modulator therapy in selected patients with severe CF-associated liver disease, provided that a multidisciplinary approach and careful clinical and laboratory monitoring are ensured.
- 22 June 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (3)
Clinical significance of comorbidities in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis
Comorbidities are important factors influencing the course and prognosis of interstitial lung diseases (ILDs). However, comparative data on the structure and clinical significance of comorbidities in idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) remain limited. The aim was to assess the prevalence and clinical significance of comorbidities in patients with IPF and HP. Methods. This single-center prospective observational study included 621 patients (229 with IPF, 392 with HP) with a 12-month follow-up. Clinical, demographic, functional, and radiological characteristics, comorbidities, the Charlson Comorbidity Index (CCI), and the GAP (Gender, Age, Physiology) index were analyzed. All patients underwent pulmonary function testing, the 6-minute walk test (6MWT), echocardiogram, and high-resolution computed tomography scan of the chest. Results. Most patients (66.2%) had 1 – 3 comorbidities, while 19.6% had ≥ 4 comorbidities. Patients with IPF had significantly higher CCI scores than those with HP ( p < 0.001). The most common comorbidities were hypertension, cardiovascular disease (CVD), gastroesophageal reflux disease, pulmonary hypertension, and diabetes mellitus. Emphysema and obstructive airway diseases were more frequent in IPF ( p < 0.05). A higher comorbidity burden and higher CCI scores correlated with higher GAP scores, shorter 6MWT distance, and more severe dyspnea (mMRC scale). The presence of ≥ 2 comorbidities was associated with increased mortality risk (AUC 0.587, p = 0.01), as was CCI ≥ 4 (AUC 0.608, p = 0.002; log-rank p = 0.007). CVD was associated with greater functional impairment and reduced exercise tolerance, while diabetes mellitus was an independent adverse prognostic factor, particularly in HP (OR 2.58, p = 0.016). Conclusion. Comorbidities are highly prevalent in both IPF and HP and significantly influence disease course and prognosis. Assessment of comorbidity burden, including the CCI, may serve as an additional risk-stratification tool in patients with fibrosing ILDs.
- 22 June 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (3)
Clinical significance of comorbidities in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis
Comorbidities are important factors influencing the course and prognosis of interstitial lung diseases (ILDs). However, comparative data on the structure and clinical significance of comorbidities in idiopathic pulmonary fibrosis (IPF) and hypersensitivity pneumonitis (HP) remain limited. The aim was to assess the prevalence and clinical significance of comorbidities in patients with IPF and HP. Methods. This single-center prospective observational study included 621 patients (229 with IPF, 392 with HP) with a 12-month follow-up. Clinical, demographic, functional, and radiological characteristics, comorbidities, the Charlson Comorbidity Index (CCI), and the GAP (Gender, Age, Physiology) index were analyzed. All patients underwent pulmonary function testing, the 6-minute walk test (6MWT), echocardiogram, and high-resolution computed tomography scan of the chest. Results. Most patients (66.2%) had 1 – 3 comorbidities, while 19.6% had ≥ 4 comorbidities. Patients with IPF had significantly higher CCI scores than those with HP ( p < 0.001). The most common comorbidities were hypertension, cardiovascular disease (CVD), gastroesophageal reflux disease, pulmonary hypertension, and diabetes mellitus. Emphysema and obstructive airway diseases were more frequent in IPF ( p < 0.05). A higher comorbidity burden and higher CCI scores correlated with higher GAP scores, shorter 6MWT distance, and more severe dyspnea (mMRC scale). The presence of ≥ 2 comorbidities was associated with increased mortality risk (AUC 0.587, p = 0.01), as was CCI ≥ 4 (AUC 0.608, p = 0.002; log-rank p = 0.007). CVD was associated with greater functional impairment and reduced exercise tolerance, while diabetes mellitus was an independent adverse prognostic factor, particularly in HP (OR 2.58, p = 0.016). Conclusion. Comorbidities are highly prevalent in both IPF and HP and significantly influence disease course and prognosis. Assessment of comorbidity burden, including the CCI, may serve as an additional risk-stratification tool in patients with fibrosing ILDs.
- 22 June 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (3)
Prognostic significance of the usual interstitial pneumonia pattern in interstitial lung diseases
The usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) is a key diagnostic hallmark of idiopathic pulmonary fibrosis (IPF). However, its prevalence and prognostic significance in other fibrosing interstitial lung diseases (ILDs), such as fibrotic hypersensitivity pneumonitis (fHP) and fibrotic ILD associated with systemic sclerosis (fILD-SSc), require a detailed comparative analysis. The aim . To perform a comparative analysis of clinical and functional characteristics, as well as disease course, in patients with IPF, fHP, and fILD-SSc with the UIP pattern on HRCT. Methods . This retrospective two-center study included a total of 554 patients: 219 with IPF, 280 with fHP, and 55 with fILD-SSc. HRCT patterns were classified as typical UIP and probable UIP by radiology experts who assessed the images. We compared clinical, functional, and hemodynamic parameters, and identified factors associated with the presence of the UIP pattern as well as predictors of disease progression over a 12-month follow-up period. Results . The typical UIP pattern was identified in 43.4% of patients with IPF, 40.7% of patients with fHP, and 16.4% of patients with fILD-SSc ( p < 0.001). Independent predictors of honeycombing in non-IPF fibrotic ILDs were male sex, high index scores GAP ( Gender, Age, Physiology ), digital clubbing, smoking pack-years, and the presence of cough ( p < 0.05 for all). Male sex (OR – 2.25; p = 0.05) and GAP index scores (OR – 1.48; p = 0.012) remained the most significant factors in the multiple regression model. The UIP pattern was a predictor of disease progression in the fHP and fILD-SSc cohort, with the OR of 2.06 (95% CI – 1.07 – 3.96, p = 0.03). Conclusion . The UIP pattern serves as a significant prognostic marker for progression in patients with fHP and fILD-SSc. This finding underscores the necessity for enhanced monitoring and consideration of early antifibrotic therapy in these patients.
- 22 June 2026
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 36 (3)
Prognostic significance of the usual interstitial pneumonia pattern in interstitial lung diseases
The usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) is a key diagnostic hallmark of idiopathic pulmonary fibrosis (IPF). However, its prevalence and prognostic significance in other fibrosing interstitial lung diseases (ILDs), such as fibrotic hypersensitivity pneumonitis (fHP) and fibrotic ILD associated with systemic sclerosis (fILD-SSc), require a detailed comparative analysis. The aim . To perform a comparative analysis of clinical and functional characteristics, as well as disease course, in patients with IPF, fHP, and fILD-SSc with the UIP pattern on HRCT. Methods . This retrospective two-center study included a total of 554 patients: 219 with IPF, 280 with fHP, and 55 with fILD-SSc. HRCT patterns were classified as typical UIP and probable UIP by radiology experts who assessed the images. We compared clinical, functional, and hemodynamic parameters, and identified factors associated with the presence of the UIP pattern as well as predictors of disease progression over a 12-month follow-up period. Results . The typical UIP pattern was identified in 43.4% of patients with IPF, 40.7% of patients with fHP, and 16.4% of patients with fILD-SSc ( p < 0.001). Independent predictors of honeycombing in non-IPF fibrotic ILDs were male sex, high index scores GAP ( Gender, Age, Physiology ), digital clubbing, smoking pack-years, and the presence of cough ( p < 0.05 for all). Male sex (OR – 2.25; p = 0.05) and GAP index scores (OR – 1.48; p = 0.012) remained the most significant factors in the multiple regression model. The UIP pattern was a predictor of disease progression in the fHP and fILD-SSc cohort, with the OR of 2.06 (95% CI – 1.07 – 3.96, p = 0.03). Conclusion . The UIP pattern serves as a significant prognostic marker for progression in patients with fHP and fILD-SSc. This finding underscores the necessity for enhanced monitoring and consideration of early antifibrotic therapy in these patients.